CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that it will report its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Tuesday, March 22, 2022.
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that it will report its fourth quarter and full year 2021 financial results before the open of the U.S. financial markets on Tuesday, March 22, 2022. Following the announcement, the Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
| Date: | Tuesday, March 22, 2022 |
| Time: | 8:30 AM Eastern Time |
| Domestic: | 877-407-9039 |
| International: | 201-689-8470 |
| Conference ID: | 13727506 |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1533175&tp_key=c99580e1e |
A live, listen-only audio webcast of the conference call can be accessed on the Investors section of the CinCor Pharma, Inc. website or at the URL above. A replay will be available on the website approximately two hours following the live call for 30 days following the call. To access the live webcast, or the subsequent archived recording, please visit the Investors section of the CinCor website at www.CinCor.com.
About CinCor
CinCor is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, a highly selective, oral small molecule inhibitor of aldosterone synthase, for the treatment of hypertension and other cardio-renal diseases.
Contacts:
Terry Coelho
CinCor Pharma, Inc.
EVP, CFO and CBDO
Investors:
Bob Yedid
LifeSci Advisors
ir@CinCor.com
